

## Anti-mycobacterial agents

Dr F. Ismail  
Dept. of Medical Microbiology  
NHLS/UP

### Properties of anti-TB drugs

- Bactericidal
- Sterilizing
- Ability to prevent resistance

### Properties of anti-TB drugs

- Isoniazid and Rifampicin are the most powerful **bactericidal** drugs, active against all populations of TB bacilli
- Pyrazinamide and streptomycin are also **bactericidal** against certain populations of TB bacilli.
  - Pyrazinamide is active in an acid environment against TB bacilli inside macrophages.
  - Streptomycin is active against rapidly multiplying extracellular bacilli
- Ethambutol is **bacteriostatic**.

### Treatment regimens

- **Intensive phase** & **continuation phase**
- **Intensive phase:** Bacilli are rapidly eradicated from sputum, clinical improvement
- **Continuation phase:** sterilizing effect of treatment eliminates the remaining viable bacilli

#### First line


- isoniazid
- rifampicin
- pyrazinamide
- ethambutol
- ~~streptomycin~~

#### Second line

- kanamycine/amikacin
- fluoro-quinolones
- cycloserine
- ethionamide
- capreomycin
- p-amino-salicylic acid

### Isoniazid

- 1952
- **Bactericidal** against actively growing TB bacilli
- **Bacteriostatic** against *non-replicating* organisms
- Inhibits synthetic pathways of mycolic acid
- Inhibits catalase peroxidase enzyme
- Well absorbed orally
- Metabolised in the liver


**Drug action: Isoniazid (INH)**

The first-line antibiotic drug isoniazid (INH) interferes with cell wall biosynthesis in *Mycobacterium tuberculosis*. INH is a prodrug and is converted to an active form by catalase peroxidase (KatG). Activated INH inhibits the action of enoyl-acyl carrier protein reductase (InhA). InhA is an important enzyme component of the fatty acid synthetase II (FAS-II) complex. FAS-II is involved in the synthesis of long-chain mycolic acids. Mycolic acids are essential structural components of the mycobacterial cell wall and are attached to the arabinogalactan layer.

immunopaedia.org

**Rifampicin**

- 1967
- Inhibits DNA-dependent RNA polymerase
- **Bactericidal** against actively replicating bacilli
- Also active against intracellular, slowly replicating bacilli
- *Some* activity against nearly dormant organisms in necrotic foci
- Well absorbed orally; penetrates CSF


**Drug action: Rifampicin (RIF)**

The first-line antibiotic drug rifampicin (RIF) interferes with RNA transcription in *Mycobacterium tuberculosis*. RIF binds to the  $\beta$ -subunit of the DNA-dependent RNA polymerase enzyme complex and inhibits transcription of messenger RNA (mRNA). The mRNA transcripts are essential requirements for protein synthesis (translation).

immunopaedia.org

**Ethambutol**

- 1961
- Interferes with cell wall biosynthesis → inhibits the action of arabinosyl transferase (membrane associated enzyme) involved in the synthesis of arabinogalactan – essential structural component of the mycobacterial cell wall
- **Bacteriostatic** *in vitro* or within macrophages

**Drug action: Ethambutol (EMB)**

The first-line antibiotic drug ethambutol (EMB) interferes with cell wall biosynthesis in *Mycobacterium tuberculosis*. EMB inhibits the action of arabinosyl transferase (EmbA). EmbA is a membrane-associated enzyme involved in the synthesis of arabinogalactan. Arabinogalactan is an essential structural component of the mycobacterial cell wall.

immunopaedia.org


**Pyrazinamide**

- Nicotinamide derivative, exact mechanism of action unknown ? Inhibits cell wall synthesis
- **Bactericidal**; optimal activity is against semi-dormant organisms in acid pH environment (intra-cellular bacilli in phagolysosome)
- Well absorbed orally, metabolized in the liver

## Streptomycin

- 1<sup>st</sup> drug to reduce TB mortality
- Inhibits protein synthesis (binds 30S unit of ribosome)
- Bactericidal against extra-cellular bacilli in alkaline medium of cavity walls.


### Drug action: Streptomycin (STR).



The first-line antibiotic drug streptomycin (STR) is an aminoglycoside that interferes with translation of messenger RNA (mRNA) transcripts in *Mycobacterium tuberculosis*. STR binds to a ribosomal protein (S12) that is a component of the 30S subunit of the ribosome complex and inhibits the synthesis of mycobacterial proteins.

immunopaedia.org

### TARGETS OF THE ANTITUBERCULOSIS AGENTS



## 1<sup>st</sup> line treatment

- 6/12 combi. Rx
- 2 months
  - Rifampicin
  - Isoniazid
  - Pyrazinamide
  - Ethambutol
- 4 months
  - Rifampicin & Isoniazid
- Combination:
  - To decrease resistance to a single agent
  - To kill both intracellular & extra cellular forms

## TREATMENT REGIMEN MONO- AND POLY DR-TB

Resistance	SA Regimen
H	Rifabutin for full duration 6-9 months RHZ + EMB <8yrs RHZE >8yrs
R	Standardized MDR-TB regimen plus H for 18 months after culture conversion
R,E (S)	MDR-TB Regimen
H,E,S	

Slide courtesy of Dr C. Majapelo

## 2<sup>nd</sup> and 3<sup>rd</sup> line agents

- MDR strains
- Toxicity to 1<sup>st</sup> line agents
- XDR
  - Capreomycin
  - Ethionamide
  - PAS
  - Cycloserine/Terizidone
  - Clofazimine
- eg.
  - Kanamycin/amikacin
  - Ethionamide
  - Cycloserine/Terizidone
  - Fluoroquinolones (levo, moxi, oflox)

## 2<sup>nd</sup> line agents

- **Para-aminosalicylic acid:** inhibits growth by impairment of folate synthesis
- **Cycloserine/Terizidone:** inhibits cell wall synthesis
- **Ethionamide:** Bacteriostatic, inhibition of oxygen-dependent mycolic acid synthesis.
- **Capreomycin:** ? Protein synthesis
- **Clofazamine:** ???

## Grouping of MDR TB Drugs

Group	Drugs
<b>Group 1:</b> First-line oral drugs	Ethambutol (E) Pyrazinamide (Z)
<b>Group 2:</b> Injectable drugs	Kanamycin (Km) Amikacin (Am) Capreomycin (Cm) Viomycin (Vm)
<b>Group 3:</b> Fluoroquinolones	Levofloxacin (Lvx) Moxifloxacin (Mfx) Gatifloxacin (Gfx)
<b>Group 4:</b> Oral bacteriostatic second-line drugs	Ethionamide (Eto) Prothionamide (Pto) Cycloserine (Cs) Terizidone (Trd) Para-Aminosalicylic Acid (PAS)
<b>Group 5:</b> Drugs of unclear efficacy (Not recommended for routine use in MDR-TB patients)	Clofazimine (Ctz) Amoxicillin/clavulanate (Amx/Clv) Clarithromycin (Clr) Azithromycin (Azr) Linezolid (Lzd) Thioacetazone (Th) Imipenem High-dose INH

WHO 2012 MDR TB Guidelines

## COMMON SIDE EFFECTS

Side effects	Agent	Management
Hearing loss	Am, Km, Cm,	Audiometry; ↓dose; give 3x/week; discontinue
Nephrotoxicity	Am, Km, Cm,	U&E; ↓dose; give 3x/week; discontinue
Hepatitis	Z, H, R, FQ, Eto/Pto, PAS	Stop therapy; LFT; Introduce drug individually
Optic neuritis	E	Stop agent, refer eye clinic
Seizures	Trd, FQ, Cs	Anticonvulsant, ↑pyridoxine to 200mg/dy; ↓dose; discontinue
Peripheral neuropathy	Trd, Km, Am, Cm, Cs, Eto, Pto, FQ	↑pyridoxine to 200mg/dy; physio; tricyclic antidepressant; discontinue

Slide courtesy of Dr C Mojapelo

## COMMON SIDE EFFECTS cont.

Side effects	Agent	Management
Psychosis	Cs, Trd, FQ, Eto/Pto	Antipsychotic drugs e.g. haloperidol; ↓dose; discontinue
Depression	Cs, Trd, FQ, Cm, Eto/Pto	↑pyridoxine to 200mg/dy; antidepressant; ↓dose; discontinue
Nausea, vomiting	Eto/Pto, PAS, Cm, Z, E	Rehydration; antiemetic; ↓dose; discontinue
Gastritis	PAS, Eto/Pto, Z, E	Administer with food; antacid; ↓dose; discontinue
Tendon rupture, muscle weakness	Mfx	

Slide courtesy of Dr C Mojapelo

## INH prophylaxis

- **Exclude active TB:** patients should be screened for signs and symptoms of active TB disease
- **IF THERE IS ANY SUSPICION THAT THE PATIENT HAS ACTIVE TB THE PATIENT SHOULD NOT BE STARTED ON IPT!**
- IPT can be given in:
  - pregnant pts
  - pts on ART
  - pts previously treated for TB

## INH prophylaxis

- **Who is Not Eligible for TB Preventive Therapy?**
  - Patients with signs and/or symptoms of TB
  - Patients with active liver disease or who are actively abusing alcohol should not be offered TB preventive therapy because of the risk of hepatotoxicity .

## INH prophylaxis

### Recommended Regimen

The standard regimen for TB preventive therapy is:

- Adults: Isoniazid (INH) 5 mg/kg/day (maximum **300 mg per day**).
- Children: Isoniazid (INH) 10 mg/kg/day (maximum **300 mg per day**).

Vitamin B6 (pyridoxine) 25 mg per day should be given concomitantly with isoniazid to prevent the occurrence of peripheral neuropathy.

The recommended duration is: **6 months of continuous treatment (can be completed over 9 months).**

If a patient has an interruption in TB preventive therapy for no more than three months, he/she can be restarted if still asymptomatic.

TB preventive therapy should be given once only. The protective effect of TB preventive therapy is expected to last for approximately 18 months.

Guidelines For Tuberculosis Preventive Therapy Among HIV  
Infected Individuals in South Africa 2010